Between slow sales, safety concerns and a likely European rejection, newly minted Alzheimer’s disease drug Aduhelm has proven more of a headache than a blessing …
Biogen’s Alzheimer’s disease drug Aduhelm has endured a headache of a launch, largely due to lingering questions about its true clinical benefit and how the …
While much of the attention on Biogen lately has centred on its launch of controversial Alzheimer’s disease drug Aduhelm, the company is also feeling the …
About 5 years ago, Topeka man, Allen Davis started to experience symptoms of Alzheimer’s Disease and Dementia. Now he’s focused on one thing. “Hopefully it’s not getting …
The drug was in development for close to two decades. Experts say that without new drugs, Alzheimer’s efforts will need to focus on prevention. High …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
